Polymeric nanoparticles loaded with the 3,5,3 ́-triiodothyroacetic acid (Triac), a thyroid hormone: Factorial design, characterization, and release kinetics

Nanotechnology, Science and Applications

Volumn 5, Issue 1, 2012, Pages 37-48

  dos Santos, Karen C ^a   da Silva, Maria Fatima Gf ^a   Pereira Filho, Edenir R ^a   Fernandes, Joao B ^a   Polikarpov, Igor ^b   Forim, Moacir R ^a  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Factorial design of experiments; HPLC analytical method; Nanoparticles; Optimization; Triac

Indexed keywords

NANOCAPSULE; NANOPARTICLE; NANOSPHERE; OIL; POLY(METHYL METHACRYLATE); POLYCAPROLACTONE; POLYMER; POLYSORBATE 80; SOLVENT; SORBITAN STEARATE; THYROID HORMONE; TIRATRICOL; WATER;

AQUEOUS SOLUTION; ARTICLE; COLLOID; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FACTORIAL DESIGN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INDEPENDENT VARIABLE; KINETICS; MAGNETISM; PARTICLE SIZE; SURFACE CHARGE; SUSTAINED DRUG RELEASE; THYROID DISEASE; VELOCITY; ZETA POTENTIAL;

EID: 84864834543     PISSN: None     EISSN: 11778903     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Koury EJ, Pawlyk AC, Berrodin TJ, Smolenski CL, Nagpal S, Deecher DC. Characterization of ligands for thyroid receptor subtypes and their interactions with co-regulators. Steroids. 2009;74(2):270-276.
2. Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. Alternate pathways of thyroid hormone metabolism. Thyroid. 2005;15(8):943-958.
3. Messier N, Laflamme L, Hamann G, Langlois MF. In vitro effect of Triac on resistance to thyroid hormone receptor mutants: potential basis for therapy. Mol Cell Endocrinol. 2001;174(1-2):59-69.
4. Collingwood TN, Adams M, Tone Y, Chatterjee VK. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome. Mol Endocrinol. 1994;8(9):1262-1277.
5. 3receptor isoform-and response element-specific. Mol Cell Endocrinol. 2000; 165(1-2):57-66.
6. Goslings B, Schwartz HL, Dillmann W, Surks MI, Oppenheimer JH. Comparison of the metabolism and distribution of L-triidothyronine triidothyroacetic acid in the rat: a possible explanation of differential hormonal potency. Endocrinology. 1976;98(3):666-675.
7. Medina-Gomez G, Calvo RM, Obregon MJ. Thermogenic effect of triiodothyroacetic acid at low doses in rat adipose tissue without adverse side effects in the thyroid axis. Am J Physiol Endocrinol Metab. 2008;294(4):E688-E697.
8. Baxter JD, Dillmann WH, West BL, et al. Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol. 2001; 76(1-5):31-42.
9. 2impregnation and by dissolution-evaporation techniques. J Control Release. 2004; 99(2):231-240.
10. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine. 2006;2(2):53-65.
11. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21.
12. Nimesh S, Manchanda R, Kumar R, et al. Preparation, characterization and in vitro drug release studies of novel polymeric nanoparticles. Int J Pharm. 2006;323(1-2):146-152.
13. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1-R4.
14. Bruns RE, Scarminio IS, de Barros Neto B. Statistical Design-Chemometrics. Amsterdam: Elsevier; 2006.
15. International Conference on Harmonization. Guidance for industry. Q2B validation of analytical procedures: methodology. November 1996. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073384.pdf. Acessed March 22, 2012.
16. Levy MY, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 1990;66(1-3): 29-37.
17. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59(6): 478-490.
18. Schaffazick SR, Pohlmann AR, Mezzalira G, Guterres SS. Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J Braz Chem Soc. 2006;17(3):562-569.
19. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanism of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24(12)12: 1113-1128.
20. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev. 2008;60(15):1638-1649.
21. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv. 2011;63(6):456-469.
22. Song X, Zhao Y, Wu W, et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm. 2008;350(1-2):320-329.
23. Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev. 2007;59(7): 546-567.
24. Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containg xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm. 2005;59(3): 491-500.
25. Mousa SA, Yalcin M, Bharali DJ, et al. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer. 2012;76(1):39-45.
26. Yalcin M, Bharali DJ, Dyskin E, et al. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid. 2010;20(3): 281-286.